Axogen, Inc. (FRA:LT3)

Market Cap	1.50B +88.3%
Revenue (ttm)	183.00M +18.7%
Net Income	-1.79M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	72.26
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	15
Open	29.20
Previous Close	29.20
Day's Range	29.20 - 29.20
52-Week Range	7.85 - 30.60
Beta	n/a
RSI	57.69
Earnings Date	Feb 24, 2026

About Axogen

Axogen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submuc...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• CEO: Michael Dale
• Employees: 452
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LT3

Financial Performance

In 2024, Axogen's revenue was $187.34 million, an increase of 17.81% compared to the previous year's $159.01 million. Losses were -$9.96 million, -54.12% less than in 2023.

Financial numbers in USD